Corrigendum to “Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity” [Journal of Controlled Release 191 (2014) 34–46] (Journal of Controlled Release (2014) 191 (34–46), (S0168365914003472), (10.1016/j.jconrel.2014.05.044));Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity

Journal of Controlled Release

Volumn 191, Issue , 2014, Pages 34-46

  Yi, Xiang ^a   Yuan, Dongfen ^a   Farr, Susan A ^b   Banks, William A ^c,d   Poon, Chi Duen ^e   Kabanov, Alexander V ^a,f  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Blood brain barrier; Brain pharmacokinetics; Leptin; Obesity; Pluronic block copolymer; Protein polymer conjugation

Indexed keywords

ALIPHATIC COMPOUNDS; BIOACTIVITY; BLOCK COPOLYMERS; BLOOD; BRAIN; CYTOLOGY; ETHYLENE; NUTRITION; PHARMACOKINETICS; POLYETHYLENE OXIDES; PROTEINS;

BLOOD-BRAIN BARRIER; LEPTIN; OBESITY; PLURONIC BLOCK COPOLYMERS; PROTEIN POLYMERS;

HORMONES;

LEPTIN; MACROGOL; PLURONIC P85; POLOXAMER; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; DRUG CARRIER; PLURONIC BLOCK COPOLYMER P85;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN UPTAKE; CONJUGATE; CONTROLLED STUDY; DRUG CONJUGATION; FOOD INTAKE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SYSTEMIC CIRCULATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BODY WEIGHT; CELL CULTURE; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; DRUG STABILITY; EATING; FEEDING BEHAVIOR; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; PATHOPHYSIOLOGY; PERMEABILITY; PHARMACEUTICS; PROCEDURES; PSYCHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-OBESITY AGENTS; BLOOD-BRAIN BARRIER; BODY WEIGHT; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG STABILITY; EATING; FEEDING BEHAVIOR; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LEPTIN; MALE; MICE; OBESITY; PERMEABILITY; POLOXALENE; TECHNOLOGY, PHARMACEUTICAL;

EID: 84906948444     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2021.07.001     Document Type: Erratum

References (56)

1. R.S. Ahima, D. Prabakaran, C. Mantzoros, D. Qu, B. Lowell, E. Maratos-Flier, J.S. Flier, Role of leptin in the neuroendocrine response to fasting, Nature 382 (1996) 250-252.
2. J.M. Friedman, J.L. Halaas, Leptin and the regulation of bodyweight inmammals, Nature 395 (1998) 763-770.
3. Y. Zhang, R. Proenca, M.Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue, Nature 372 (1994) 425-432.
4. W.A. Banks, A.J. Kastin, W. Huang, J.B. Jaspan, L.M. Maness, Leptin enters the brain by a saturable system independent of insulin, Peptides 17 (1996) 305-311.
5. X.S.Wu-Peng, S.C. Chua Jr., N. Okada, S.M. Liu, M. Nicolson, R.L. Leibel, Phenotype of the obese Koletsky (f) rat due to Tyr763Stopmutation in the extracellular domain of the leptin receptor (Lepr): evidence for deficient plasma-to-CSF transport of leptin in both the Zucker and Koletsky obese rat, Diabetes 46 (1997) 513-518.
6. M.W. Schwartz, S.C.Woods, D. Porte Jr., R.J. Seeley, D.G. Baskin, Central nervous system control of food intake, Nature 404 (2000) 661-671.
7. B.E. Levin, A.A. Dunn-Meynell, W.A. Banks, Obesity-prone rats have normal blood- brain barrier transport but defective central leptin signaling before obesity onset, Am. J. Physiol. 286 (2004) R143-R150.
8. J.D. Roth, B.L. Roland, R.L. Cole, J.L. Trevaskis, C.Weyer, J.E. Koda, C.M. Anderson, D.G. Parkes, A.D. Baron, Leptin responsiveness restored by amylin agonism in dietinduced obesity: evidence from nonclinical and clinical studies, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 7257-7262.
9. E. Ravussin, S.R. Smith, J.A. Mitchell, R. Shringarpure, K. Shan, H. Maier, J.E. Koda, C. Weyer, Enhanced weight loss with pramlintide/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy, Obesity (Silver Spring) 17 (2009) 1736-1743.
10. M. Van Heek, D.S. Compton, C.F. France, R.P. Tedesco, A.B. Fawzi, M.P. Graziano, E.J. Sybertz, C.D. Strader, H.R. Davis Jr., Diet-induced obese mice develop peripheral, but not central, resistance to leptin, J. Clin. Invest. 99 (1997) 385-390.
11. W.A. Banks, C.L. Farrell, Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible, Am. J. Physiol. Endocrinol. Metab. 285 (2003) E10-E15.
12. C.L. Adam, P.A. Findlay, Decreased blood-brain leptin transfer in an ovine model of obesity and weight loss: resolving the cause of leptin resistance, Int. J. Obes. (Lond.) 34 (2010) 980-988.
13. W.A. Banks, Is obesity a disease of the blood-brain barrier? Physiological, pathological, and evolutionary considerations, Curr. Pharm. Des. 9 (2003) 801-809.
14. J.L. Halaas, C. Boozer, J. Blair-West, N. Fidahusein, D.A. Denton, J.M. Friedman, Physiological response to long-term peripheral and central leptin infusion in lean and obese mice, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 8878-8883.
15. C. LeBel, A. Bourdeau, D. Lau, P. Hunt, Biologic response to peripheral and central administration of recombinant human leptin in dogs, Obes. Res. 7 (1999) 577-585.
16. S.B. Heymsfield, A.S. Greenberg, K. Fujioka, R.M. Dixon, R. Kushner, T. Hunt, J.A. Lubina, J. Patane, B. Self, P. Hunt, M. McCamish, Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial, JAMA 282 (1999) 1568-1575.
17. A. Kahler, N. Geary, L.A. Eckel, L.A. Campfield, F.J. Smith, W. Langhans, Chronic administration of OB protein decreases food intake by selectively reducing meal size in male rats, Am. J. Physiol. 275 (1998) R180-R185.
18. C.J. Hukshorn, F.M. van Dielen, W.A. Buurman, M.S. Westerterp-Plantenga, L.A. Campfield, W.H. Saris, The effect of pegylated recombinant human leptin (PEGOB) on weight loss and inflammatory status in obese subjects, Int. J. Obes. Relat. Metab. Disord. 26 (2002) 504-509.
19. M.P. Lejeune, C.J. Hukshorn, W.H. Saris, M.S.Westerterp-Plantenga, Effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB) treatment of overweight men, Int. J. Obes. Relat. Metab. Disord. 27 (2003) 1494-1499.
20. S.E. Haun, J.R. Kirsch, M.A. Helfaer, K.L. Kubos, R.J. Traystman, Polyethylene glycolconjugated superoxide dismutase fails to augment brain superoxide dismutase activity in piglets, Stroke 22 (1991) 655-659.
21. D.Wu, W.M. Pardridge, Neuroprotection with noninvasive neurotrophin delivery to the brain, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 254-259.
22. W.M. Pardridge, D. Wu, T. Sakane, Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, Pharm. Res. 15 (1998) 576-582.
23. E. Elinav, L. Niv-Spector, M. Katz, T.O. Price, M. Ali, M. Yacobovitz, G. Solomon, S. Reicher, J.L. Lynch, Z. Halpern, W.A. Banks, A. Gertler, Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity, Endocrinology 150 (2009) 3083-3091.
24. K.M. Lo, J. Zhang, Y. Sun, B. Morelli, Y. Lan, S. Lauder, B. Brunkhorst, G. Webster, S. Hallakou-Bozec, L. Doare, S.D. Gillies, Engineering a pharmacologically superior form of leptin for the treatment of obesity, Protein Eng. Des. Sel. 18 (2005) 1-10.
25. Y. Wu, C. Cain-Hom, L. Choy, T.J. Hagenbeek, G.P. de Leon, Y. Chen, D. Finkle, R. Venook, X. Wu, J. Ridgway, D. Schahin-Reed, G.J. Dow, A. Shelton, S. Stawicki, R.J. Watts, J. Zhang, R. Choy, P. Howard, L. Kadyk, M. Yan, J. Zha, C.A. Callahan, S.G. Hymowitz, C.W. Siebel, Therapeutic antibody targeting of individual Notch receptors, Nature 464 (2010) 1052-1057.
26. F. Herve, N. Ghinea, J.M. Scherrmann, CNS delivery via adsorptive transcytosis, AAPS J. 10 (2008) 455-472.
27. I. Kovalszky, E. Surmacz, L. Scolaro, M. Cassone, R. Ferla, A. Sztodola, J. Olah, M.P. Hatfield, S. Lovas, L. Otvos Jr., Leptin-based glycopeptide induces weight loss and simultaneously restores fertility in animal models, Diabetes Obes. Metab. 12 (2010) 393-402.
28. W.A. Banks, Enhanced leptin transport across the blood-brain barrier by alpha 1- Adrenergic agents, Brain Res. 899 (2001) 209-217.
29. T.O. Price, S.A. Farr, X. Yi, S. Vinogradov, E. Batrakova, W.A. Banks, A.V. Kabanov, Transport across the blood-brain barrier of pluronic leptin, J. Pharm. Exp. Ther. 333 (2010) 253-263.
30. X. Yi, E. Batrakova, W.A. Banks, S. Vinogradov, A.V. Kabanov, Protein conjugation with amphiphilic block copolymers for enhanced cellular delivery, Bioconjug. Chem. 19 (2008) 1071-1077.
31. L. Whitmore, B.A. Wallace, Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases, Biopolymers 89 (2008) 392-400.
32. L. Whitmore, B.A. Wallace, DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data, Nucleic Acids Res. 32 (2004) W668-W673.
33. J.R. Wisniewski, A. Zougman, N. Nagaraj, M. Mann, Universal sample preparation method for proteome analysis, Nat. Methods 6 (2009) 359-362.
34. G. Saito, J.A. Swanson, K.D. Lee, Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities, Adv. Drug Deliv. Rev. 55 (2003) 199-215.
35. V. Cuchelkar, P. Kopeckova, J. Kopecek, Synthesis and biological evaluation of disulfide-linked HPMA copolymer-mesochlorin e6 conjugates, Macromol. Biosci. 8 (2008) 375-383.
36. J.E. Wright, S.A. Gittens, G. Bansal, P.I. Kitov, D. Sindrey, C. Kucharski, H. Uludag, A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages, Biomaterials 27 (2006) 769-784.
37. P. Mistrik, F. Moreau, J.M. Allen, BiaCore analysis of leptin-leptin receptor interaction: evidence for 1:1 stoichiometry, Anal. Biochem. 327 (2004) 271-277.
38. J.E. Morley, M.M. Alshaher, S.A. Farr, J.F. Flood, V.B. Kumar, Leptin and neuropeptide Y (NPY) modulate nitric oxide synthase: further evidence for a role of nitric oxide in feeding, Peptides 20 (1999) 595-600.
39. C.S. Patlak, R.G. Blasberg, J.D. Fenstermacher, Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data, J. Cereb. Blood Flow Metab. 3 (1983) 1-7.
40. R.G. Blasberg, J.D. Fenstermacher, C.S. Patlak, Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes, J. Cereb. Blood Flow Metab. 3 (1983) 8-32.
41. X. Yi, M.C. Zimmerman, R. Yang, J. Tong, S. Vinogradov, A.V. Kabanov, Pluronicmodified superoxide dismutase 1 attenuates angiotensin II-induced increase in intracellular superoxide in neurons, Free Radic. Biol. Med. 49 (2010) 548-558.
42. J. Snider, C. Neville, L.C. Yuan, J. Bullock, Characterization of the heterogeneity of polyethylene glycol-modified superoxide dismutase by chromatographic and electrophoretic techniques, J. Chromatogr. 599 (1992) 141-155.
43. G. Salomon, L. Niv-Spector, E.E. Gussakovsky, A. Gertler, Large-scale preparation of biologically active mouse and rat leptins and their L39A/D40A/F41A muteins which act as potent antagonists, Protein Expr. Purif. 47 (2006) 128-136.
44. T.L. Cheng, B.M. Chen, L.Y. Chan, P.Y.Wu, J.W. Chern, S.R. Roffler, Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs, Cancer Immunol. Immunother. 44 (1997) 305-315.
45. T.L. Cheng, C.M. Cheng, B.M. Chen, D.A. Tsao, K.H. Chuang, S.W. Hsiao, Y.H. Lin, S.R. Roffler, Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles, Bioconjug. Chem. 16 (2005) 1225-1231.
46. T.L. Cheng, P.Y. Wu, M.F. Wu, J.W. Chern, S.R. Roffler, Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM, Bioconjug. Chem. 10 (1999) 520-528.
47. K.H. Chuang, S.C. Tzou, T.C. Cheng, C.H. Kao, W.L. Tseng, J. Shiea, K.W. Liao, Y.M. Wang, Y.C. Chang, B.J. Huang, C.J.Wu, P.Y. Chu, S.R. Roffler, T.L. Cheng, Measurement of poly(ethylene glycol) by cell-based anti-poly(ethylene glycol) ELISA, Anal. Chem. 82, 2010, 2355-2362.
48. T. Hanada, N.N. Noda, Y. Satomi, Y. Ichimura, Y. Fujioka, T. Takao, F. Inagaki, Y. Ohsumi, The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy, J. Biol. Chem. 282 (2007) 37298-37302.
49. N.M. Tsai, T.L. Cheng, S.R. Roffler, Sensitive measurement of polyethylene glycolmodified proteins, BioTechniques 30 (2001) 396-402.
50. W.A. Banks, R.N. McLay, A.J. Kastin, U. Sarmiento, S. Scully, Passage of leptin across the blood-testis barrier, Am. J. Physiol. 276 (1999) E1099-E1104.
51. G. Sahay, D.Y. Alakhova, A.V. Kabanov, Endocytosis of nanomedicines, J. Control. Release 145 (2010) 182-195.
52. G. Sahay, V. Gautam, R. Luxenhofer, A.V. Kabanov, The utilization of pathogen-like cellular trafficking by single chain block copolymer, Biomaterials 31 (2010) 1757-1764.
53. K.A. Witt, T.J. Gillespie, J.D. Huber, R.D. Egleton, T.P. Davis, Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability, Peptides 22 (2001) 2329-2343.
54. W. Pan, A.J. Kastin, Changing the chemokine gradient: CINC1 crosses the blood- brain barrier, J. Neuroimmunol. 115 (2001) 64-70.
55. B. Carpenter, G.R. Hemsworth, Z. Wu, M. Maamra, C.J. Strasburger, R.J. Ross, P.J. Artymiuk, Structure of the human obesity receptor leptin-binding domain reveals the mechanism of leptin antagonism by a monoclonal antibody, Structure 20 (2012) 487-497.
56. H. Hsuchou, A.J. Kastin, H. Tu, E.N. Markadakis, K.P. Stone, Y.Wang, S.B. Heymsfield, S.S. Chua Jr., S. Obici, I.J. Magrisso, W. Pan, Effects of cell-type specific leptin receptor mutation on leptin transport across the BBB, Peptides 32 (2011) 1392-1399.